Pfiz­er yanks blood pres­sure meds amidst on­go­ing, in­dus­try-wide ni­trosamine prob­lems

For four con­sec­u­tive months last year, Pfiz­er yanked its an­ti-smok­ing drug Chan­tix off of the shelves, and halt­ed dis­tri­b­u­tion, af­ter lots were found con­t­a­m­i­nat­ed with ni­trosamine or ND­MA. Now, the phar­ma is re­call­ing about a dozen lots of its blood pres­sure med­ica­tion Ac­curet­ic, as well as two au­tho­rized gener­ics, af­ter de­tect­ing traces of the po­ten­tial­ly can­cer-caus­ing agent.

Six lots of Ac­curet­ic tablets will be pulled, along with a lot of quinapril and hy­drochloroth­iazide and four lots of quinapril HCl/ hy­drochloroth­iazide tablets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER